Program
brimonidine
Also written as “Brimonidine”, “Brimonidine Tartrate” and “CD07805/47 Gel”.
Its studies are mostly in Glaucoma · Rosacea · Glaucoma, Open-Angle · Conjunctivitis, Allergic · Hyperemia, led by 10 companies.
Drug pageBrimonidine: every studyMany companies study it; this page follows only the 52 they lead. All 104 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbbVieits history only | 220 open or running | phase 4since Apr 6, 2007 | Sep 12, 2005 | none ahead |
| Galderma Groupits history only | 100 open or running | phase 4since Sep 23, 2014 | Jun 12, 2008 | none ahead |
| Bausch Health Companiesits history only | 70 open or running | phase 3since Oct 8, 2013 | Oct 8, 2013 | none ahead |
| Eye Therapiesits history only | 30 open or running | phase 2since Jan 10, 2011 | Jan 10, 2011 | none ahead |
| Ocugen | 30 open or running | phase 3since Jul 9, 2018 | Oct 10, 2017 | none ahead |
| Alconits history only | 20 open or running | phase 4since Dec 1, 2008 | May 28, 2003 | none ahead |
| Tarian Pharmaits history only | 22 open or running | phase 2since Jan 23, 2025 | Jan 23, 2025 | none ahead |
| Biogenits history only | 10 open or running | phase 4since Oct 1, 2015 | Oct 1, 2015 | none ahead |
| Innovative Medicalits history only | 10 open or running | phase 4since Jun 30, 2006 | Jun 30, 2006 | none ahead |
| Teva Pharmaceutical Industriesits history only | 10 open or running | phase 3since Oct 31, 2014 | Oct 31, 2014 | none ahead |
Also a collaborator on its studies: ORA and Eurotrials Brasil Consultores Cientificos Ltda.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Ocugen only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 10, 2017First study: phase 2 study in Dry Eye SyndromesFirst studyNCT03418727 · 84 enrolled · United States
- Jul 9, 2018Phase 3 study in Graft vs Host DiseaseNCT03591874 · 59 enrolled · United States
- Dec 20, 2018Phase 3 study in Dry Eye SyndromesNCT03785340 · 252 enrolled · United States
TargetBeta
“Adrenergic receptor alpha-2 agonist”ChEMBL 37, by rule
Other programs on the same three targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Dexmedetomidinerule | Pfizer | phase 4 | 46 |
| Oxymetazolinerule | AbbVie | phase 4 | 20 |
| Phentolaminerule | opus-genetics-inc | phase 4 | 18 |
| Epinephrinerule | nasus-pharma | phase 4 | 17 |
| tizanidinerule | Teva Pharmaceutical Industries | phase 4 | 11 |
| Clonidinerule | pharmafina | phase 4 | 5 |
| lofexidinerule | uswm-llc-dba-us-worldmeds | phase 3 | 15 |
Studies
All 3 Ocugen leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03785340Dry Eye Syndromes · United States | 3 | Completed | Feb 25, 2019 | 252 |
| NCT03591874Graft vs Host Disease · United States | 3 | Terminated | Apr 30, 2020 | 59 |
| NCT03418727Dry Eye Syndromes · United States | 2 | Completed | Mar 29, 2018 | 84 |
How it is read
Names in the registry
- “Brimonidine”, 4 entries
- “Brimonidine Tartrate”, 4 entries
- “CD07805/47 Gel”, 4 entries
- “CD07805/47”, 3 entries
- “400 µg Brimonidine Tartrate Implant”, 3 entries
Conditions, from the studies’ own filings
- Glaucoma, 10 studies
- Rosacea, 9 studies
- Glaucoma, Open-Angle, 8 studies
- Conjunctivitis, Allergic, 4 studies
- Hyperemia, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.